We are redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients.
More About Us
The GRO Platform
The GRO platform expands the amino acid alphabet to overcome the limitations of protein therapeutics currently impeding the treatment of disease
We’re delivering on the long-awaited promise of protein therapeutics by solving the intrinsic limitations of proteins on potency, stability, and function. The GRO platform shortens development timelines and is the only system capable of seamlessly scaling production of NSAA (non-standard amino acid) proteins to meet clinical needs.
LEARN MORE
Our Pipeline
Today, we’re focused on our first two families of NSAA chemistries to drive our product pipeline
GRObio is advancing its first two families of NSAA chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side-effects of protein-based therapies.
LEARN MORE
Featured News
GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship
BOSTON, April 11, 2023 - GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics,…
Read More
The 2023 PharmaVoice Year in Preview
Every year brings its own distinct changes. For the life sciences industry, 2022 was marked by challenges such as the ongoing influence of the pandemic, a turbulent economy and a…
Read More
Finding Genius: Engineering Proteins To Enhance Medicine With GRO Biosciences CEO Daniel J. Mandell
In this episode, we sit down with scientist and entrepreneur Daniel J. Mandell, Ph.D. Daniel is the Chief Executive Officer, Co-Founder, and Director of GRO Biosciences, a genome engineering, computational…
Read More
